Royalty Pharma plc (RPRX)
Royalty Pharma plc operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in New York, NY, US. The stock last traded at $59.09, up 2.24% on the session, giving a market capitalisation of $26.19B. On trailing twelve-month figures it carries a trailing P/E of 24.52, a net margin of 32.1%. Its beta of 0.42 implies it has historically moved less than the broad market.
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Royalty Pharma plc is most often compared with the following Healthcare names: